Jefferies initiated coverage of VectivBio with a rating of Buy and set a new price target of $18.00

Piper Sandler initiated coverage of VectivBio with a rating of Overweight and set a new price target of $23.00

SVB Leerink initiated coverage of VectivBio Holding with a rating of Outperform and set a new price target of $28.00

SVB Leerink initiated coverage of VectivBio Holding with a rating of Overweight and set a new price target of $28.00

Credit Suisse initiated coverage of VectivBio with a rating of Outperform and set a new price target of $24.00

BofA Securities initiated coverage of VectivBio with a rating of Buy and set a new price target of $19.00

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

- Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, an

BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET. A live webcast will be accessible under ‘Events & Presentations' in the ‘Investors & Media' section of VectivBio's website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio's website approximately two hours after the conference call and will be available for thirty days

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland. The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors. In view of the ongoing COVID-19 pandemic, and in accordance with the Ordinance 3 of the Swiss Federal C

$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update. Highlights include the announcement of $5 million of debt financing and the appointment of an additional member to Cingulate's Board of Directors. "Cingulate continues to advance its mission in bringin

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in JapanLoan facility established with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting the company access of up to $75 million, with a minimum commitment to draw down $10 millionVectivBio to hold FY 2021 Earnings Call and Business Update on April 7, 2022, at 8:00 a.m. ET BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

Santarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis' board. "I'm pleased to welcome Luca as chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company," said Dr. Roberto Iacone, Chief Executive Officer of Alentis. "I very much want to thank Rafaèle for her trem

BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications.  Mr. Malloy's two decades of investor relations and commercial leadership experience strengthens VectivBio as it continues to evolve into a fully integrated, rare disease leader.  "Pat has a broad range of experience in not only investor relations, but also commercial and strategic leadership in the biotech and rare disease spaces," said Luca Sant

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (IMDs)- -IND Application for Apraglutide for Acute Graft-Versus-Host Disease (aGVHD) Cleared by FDA; First Patient in Expected 1Q 2022, Interim Data Expected 2H 2022- BASEL, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today provided a bu

BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Scott Applebaum as Chief Legal Officer & Corporate Secretary. Mr. Applebaum brings over two decades of legal, regulatory and operational experience in the biopharmaceutical industry to VectivBio. "Scott has a great understanding of the legal and regulatory intricacies of the biotech and rare disease space," said Luca Santarelli, M.D., Founder and CEO of VectivBio. "His knowledge and leadership will help guide us as we advance our Phase 3

Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of apraglutide in short bowel syndrome and graft versus host disease, and expansion of its rare disease product portfolio BASEL, Switzerland, May 25, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the appointment of Omar Khwaja, M.D.,

BOSTON and LONDON, May 5, 2021 /PRNewswire/ -- The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, announces the appointment of Luca Santarelli, M.D., as new Chair of its Scientific Advisory Board (SAB).  Dr. Santarelli is an entrepreneurial pharmaceutical executive with a background in academic research and more than 20 years of experience in R&D and as a biotech CEO. He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. In his new role with DDF, Dr. Sant

Over the past 3 months, 4 analysts have published their opinion on VectivBio Holding (NASDAQ:VECT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 3 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $19.0 versus the current price of VectivBio Holding at $16.5, implying upside. Below is a summary of how these 4 analysts rated VectivBio Holding over the past 3 months. The greater the number o

Upgrades MoffettNathanson upgraded the previous rating for Zoom Video Communications Inc (NASDAQ:ZM) from Underperform to Market Perform. Zoom Video Comms earned $1.16 in the first quarter, compared to $1.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $124.05 and a 52-week-low of $60.45. Zoom Video Comms closed at $71.41 at the end of the last trading period. Evercore ISI Group upgraded the previous rating for CCC Intelligent Solutions Holdings Inc (NASDAQ:CCCS) from In-Line to Outperform. For the first quarter, CCC Intelligent Solutions had an EPS of $0.07, compared to year-ago quarter EPS of $0.08. The current stock performance of CCC Intelligent Solutions sh

Piper Sandler analyst Christopher Raymond downgrades VectivBio Holding (NASDAQ:VECT) from Overweight to Neutral and lowers the price target from $25 to $17.

SVB Leerink analyst Thomas Smith downgrades VectivBio Holding (NASDAQ:VECT) from Outperform to Market Perform and lowers the price target from $30 to $17.

Credit Suisse analyst Tiago Fauth downgrades VectivBio Holding (NASDAQ:VECT) from Outperform to Neutral and lowers the price target from $22 to $17.

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ:VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days.  Headquartered in Basel, Switzerland, VectivBio is a clinical-stage biotechnology company focused on discovering and developing treatments for Short Bowel Syndrome with Intestinal Failure (SBS-IF) and acute Graft versus Host Disease (aGvHD).  VectivBio's lead investigational asset, apraglutide, is a next-gen

Gainers Greenhill & Co., Inc. (NYSE:GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. AVROBIO, Inc. (NASDAQ:AVRO) gained 93.5% to $1.50 after the company announced it would sell its gene therapy program to Novartis for $87.5 million. Microbot Medical Inc. (NASDAQ:MBOT) rose 66% to $2.0450 after the company announced it achieved a 100% success rate for the LIBERTY system in an extensive pre-clinical animal study performed by leading European physicians. Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares gained 39.7% to $12.45 after the company announced results of its phase 2 study to treat liver function. VectivBio Holding AG (

U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Friday. Here are some big stocks recording gains in today’s session. Greenhill & Co., Inc. (NYSE:GHL) shares rose 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. VectivBio Holding AG (NASDAQ:VECT) gained 38.5% to $16.20 after Ironwood Pharmaceuticals announced it would acquire the company for $17 per share. Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shares surged 33.5% to $4.9375. Tang Capital Partners, Concentra sent acquisition proposal to Atea Pharmaceuticals with terms to acquire all of its outstanding common stock. Outlook Therapeutics, Inc. (NASDAQ:OTLK) climbed 17.2% t

VectivBio Holding AG (NASDAQ:VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) agreed to acquire VectivBio. What Happened: VectivBio and Ironwood entered into a definitive agreement in which Ironwood will acquire VectivBio for $17 per share in an all-cash transaction. The deal has an estimated aggregate consideration of approximately $1 billion.  "We are delighted to enter into this agreement with Ironwood to advance the development and commercialization of innovative therapies targeted at GI and rare diseases, which is the mission of VectivBio," said Luca Santarelli, founder and CEO of VectivBio. Ironwood is focused on V

U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to 12,669.27. The S&P 500, also rose, gaining, 0.08% to 4,195.41. Check This Out: Top 5 Consumer Stocks That May Explode In May  Leading and Lagging Sectors Communication services shares rose by 1.5% on Monday. Meanwhile, top gainers in the sector included Grindr Inc. (NYSE:GRND), up 5%, and Vimeo, Inc. (NASDAQ:VMEO), up 5%. In trading on Monday, consumer staples shares fell 0.4%.  Top Headline Nordic American Tankers Limited (NYSE:NAT) reported better-than-expected first-quarter resul